Page last updated: 2024-11-04

terazosin and Syndrome

terazosin has been researched along with Syndrome in 14 studies

Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."9.22A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016)
"To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome."9.11Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004)
"We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome."9.10Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003)
"To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."5.22A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016)
"To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome."5.11Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004)
"We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome."5.10Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003)
"To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery."4.87Risk factors for intraoperative floppy iris syndrome: a meta-analysis. ( Chatziralli, IP; Sergentanis, TN, 2011)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (57.14)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Pierce, H1
Fainberg, J1
Gaffney, C1
Aboukhashaba, A1
Khan, A1
Kashanian, J1
Zhang, XY1
Luo, SB1
Zhang, JY1
Meng, ZC1
Wang, J1
Yan, D1
Liang, K1
Xu, Z1
Zhang, Y1
Shamie, N1
Daneshmand, S1
Mamalis, N1
Prata, TS1
Palmiero, PM1
Angelilli, A1
Sbeity, Z1
De Moraes, CG1
Liebmann, JM1
Ritch, R1
Chatziralli, IP1
Sergentanis, TN1
Casuccio, A1
Cillino, G1
Pavone, C1
Spitale, E1
Cillino, S1
Cheah, PY2
Liong, ML2
Yuen, KH2
Teh, CL2
Khor, T2
Yang, JR2
Yap, HW2
Krieger, JN2
Minervini, A1
Lapini, A1
Serni, S1
Carini, M1
Schwinn, DA1
Afshari, NA1
Paick, JS1
Lee, SC1
Ku, JH1
Seppi, K1
Puschban, Z1
Stefanova, N1
Scherfler, C1
Mueller, J1
Poewe, W1
Wenning, GK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596]Phase 463 participants (Actual)Interventional2015-10-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for terazosin and Syndrome

ArticleYear
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
    Ophthalmology, 2011, Volume: 118, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; In

2011

Trials

5 trials available for terazosin and Syndrome

ArticleYear
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
    Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:5

    Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combi

2017
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
    International urology and nephrology, 2016, Volume: 48, Issue:1

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Huma

2016
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
    The Journal of urology, 2003, Volume: 169, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prazos

2003
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
    Urology, 2004, Volume: 64, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans

2004
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.
    Prostate cancer and prostatic diseases, 2006, Volume: 9, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Combined Modality Therapy; Humans; Magnetics; Male; Middle Aged

2006

Other Studies

8 other studies available for terazosin and Syndrome

ArticleYear
Postorgasmic illness syndrome: potential new treatment options for a rare disorder.
    Scandinavian journal of urology, 2020, Volume: 54, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Humans; Male; Orgasm; Prazosin; Quinazolines; Sexual

2020
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome.
    Urology, 2016, Volume: 97

    Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female;

2016
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
    Journal of cataract and refractive surgery, 2008, Volume: 34, Issue:7

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi

2008
Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.
    Ophthalmology, 2009, Volume: 116, Issue:5

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Sectional Studies

2009
Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
    Journal of cataract and refractive surgery, 2011, Volume: 37, Issue:8

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cohort Studies; Doxazosin; Drug Combinations; Humans;

2011
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
    Urology, 2005, Volume: 66, Issue:1

    Topics: Chronic Disease; Humans; Male; Pelvic Pain; Prazosin; Prostatitis; Syndrome; Time Factors

2005
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
    Ophthalmology, 2005, Volume: 112, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Do

2005
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Nature medicine, 2001, Volume: 7, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models,

2001